A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B‐induced decompensated liver cirrhosis

A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord... IntroductionThough liver owns a considerable inherent regenerate ability, continuous and chronic injury leads to the onset of hepatic cirrhosis. Various stimuli such as hepatitis virus, alcohol, drugs, and autoimmune assault by hepatic cells can touch off hepatocyte apoptosis, damage the endothelial barrier, accumulate the inflammatory cells, and activate hepatic stellate cells. In China, chronic hepatitis B virus (HBV) infection is the major factor of liver cirrhosis (LC). LC generally progresses irreversibly into a decompensated phase, which is featured by a sequence of clinical manifestations, including ascites, variceal hemorrhage, and hepatic encephalopathy. Apparently, hepatic cirrhosis is easy to progress to liver failure, and the condition of patient in hepatic failure with accompanying LC is more serious, and the prognosis is worse. Currently, the most effective therapy for end‐stage LC is liver transplantation. However, transplantation is limited by a shortage of donor organs, surgical complications, immunological rejection, and high medical expense.While originally isolated from bone marrow, mesenchymal stem cells (MSCs) are widely distributed in the postnatal organism and adult organs or tissues, which are multipotent stromal cells with self‐renewing potential characterized by their capacity to differentiate into the cells of the mesodermal and ectodermal lineage. Furthermore, a large quantity of experiments http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Gastroenterology and Hepatology Wiley

A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B‐induced decompensated liver cirrhosis

Loading next page...
 
/lp/wiley/a-study-about-immunomodulatory-effect-and-efficacy-and-prognosis-of-VcW4QSEFUr
Publisher
Wiley
Copyright
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
ISSN
0815-9319
eISSN
1440-1746
D.O.I.
10.1111/jgh.14081
Publisher site
See Article on Publisher Site

Abstract

IntroductionThough liver owns a considerable inherent regenerate ability, continuous and chronic injury leads to the onset of hepatic cirrhosis. Various stimuli such as hepatitis virus, alcohol, drugs, and autoimmune assault by hepatic cells can touch off hepatocyte apoptosis, damage the endothelial barrier, accumulate the inflammatory cells, and activate hepatic stellate cells. In China, chronic hepatitis B virus (HBV) infection is the major factor of liver cirrhosis (LC). LC generally progresses irreversibly into a decompensated phase, which is featured by a sequence of clinical manifestations, including ascites, variceal hemorrhage, and hepatic encephalopathy. Apparently, hepatic cirrhosis is easy to progress to liver failure, and the condition of patient in hepatic failure with accompanying LC is more serious, and the prognosis is worse. Currently, the most effective therapy for end‐stage LC is liver transplantation. However, transplantation is limited by a shortage of donor organs, surgical complications, immunological rejection, and high medical expense.While originally isolated from bone marrow, mesenchymal stem cells (MSCs) are widely distributed in the postnatal organism and adult organs or tissues, which are multipotent stromal cells with self‐renewing potential characterized by their capacity to differentiate into the cells of the mesodermal and ectodermal lineage. Furthermore, a large quantity of experiments

Journal

Journal of Gastroenterology and HepatologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off